FRANKLIN LAKES, N.J. (Jan. 13, 2021) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of the BD® AbSeq Immune Discovery Panel (IDP), a state-of-the-art, pre-titrated antibody-oligo based discovery tool designed to investigate 30 immune markers in a single experiment.
The BD® AbSeq IDP builds upon the advances of the BD® AbSeq Assay, which analyzes protein expression at the single-cell level using next-generation sequencing. The BD® AbSeq IDP now offers researchers convenience, reliability and flexibility as both a multiomics-enabled and cost-efficient tool to aid in immune research and discovery.
Also built upon BD antibody-oligo based technology, the BD® AbSeq IDP consists of 30 different specificities targeting most major immune markers, conveniently grouped together in a single tube. The panel helps enable immune cell type identification and the analysis of their activation and suppression status. Further, it allows researchers to include additional immune markers of interest.
“Antibody panels can have a significant impact on both basic and translational science. A well-designed panel allows for rapid implementation and reduces delays in experimental set up,” says Professor Fabio Luciani, Associate Professor, School of Medical Sciences, University of New South Wales, Australia. “Combined with single-cell technologies, high-dimensional antibody panels with oligo barcodes are powerful tools to identify the broad spectrum of immune cells in disease samples, and they also inform on molecular and cellular profiles that possibly drive further understanding of the disease.”
The IDP is designed to work on the BD Rhapsody™ Single-Cell Analysis System, alongside RNA and multiplexing assays.
“The 30-plex BD® AbSeq IDP helps enable sequencing-based immune cell phenotyping, which fits well among a broad audience in immunology and immuno-oncology fields,” said Xuhuai Ji, PhD, Genomics Manager, The Human Immune Monitoring Center (HIMC), Stanford Medicine Institute for Immunity, Transplantation and Infection, Palo Alto, California. “This new approach makes it easier for researchers to start designing and begin their new projects on the BD Rhapsody™ Single-Cell Analysis System.”
The BD® AbSeq IDP offers immunology researchers multiple benefits:
- One-Tube Convenience: 30 pre-titrated antibodies against major immune markers in a single tube
- Ease of Use: Lyophilized format; simply reconstitute to stain samples
- Reliability: Accompanied by comprehensive performance test data
- Flexibility: A great backbone panel that allows easy addition of more antibodies of interest
- Multiomics Enabled: Works along with RNA and multiplexing assays
- Great Value: Manage your sequencing costs
“With the development and availability of the BD® AbSeq IDP, BD expands our commitment to single-cell research and delivers robust, easy-to-use tools that offer researchers valuable and deeper insights,” said Brian Lilhanand, leader for Single-Cell Multiomics at BD Biosciences for BD. “Single-cell analysis tools like the BD® AbSeq Assay and BD Rhapsody™ Single-Cell Analysis System have helped expand our customers' ability to study cells of interest and drive rapid advancements in immunology, including drug treatment response and cell therapy.”
About the BD Single-Cell Multiomics Portfolio
To further knowledge of the immune system, BD empowers immunology researchers with a range of tools for multiomic analysis. BD advances the future of immunology research with the BD® AbSeq Assay, an innovative product that leverages 40 years of BD leadership in immunology research. The BD® AbSeq Portfolio currently encompasses more than 450 different clones of both mouse and human specificities. In addition, BD also offers customers the option to conjugate their in-house antibodies of interest with oligos compatible with the BD Rhapsody™ Single-Cell Analysis System to generate custom BD® AbSeq Antibodies.
BD has continued to build on its BD Rhapsody™ Single-Cell Analysis System, a complete system of reagents, instruments, software and targeted gene panels to offer additional single-cell analysis capabilities. These include the BD Rhapsody™ Whole Transcriptome Analysis Amplification Kit designed to analyze the entire transcriptome, targeted RNA panels and VDJ CDR3 protocols that enable researchers to identify TCR and BCR sequence information. Importantly, all BD assays are multiomics enabled and allow researchers to simultaneously analyze protein and RNA information at the single-cell level.
More information on the new BD® AbSeq Immune Discovery Panel is available here.
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com.
The products described in this announcement are for research use only and not for diagnostic or therapeutic use.